{"filing":{"accession_number":"0001140361-26-029960","cik":"0000874015","ticker":"IONS","company_name":"IONIS PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"ef20078953_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/874015/000114036126029960/ef20078953_8k.htm"},"events":[{"id":21406,"run_id":19307,"accession_number":"0001140361-26-029960","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Ionis Pharmaceuticals' financial results for the quarter ended June 30, 2026. The Item 2.02 filing explicitly states \"Ionis Pharmaceuticals, Inc. (the 'Company') issued a press release announcing the Company's financial results for the quarter ended June 30, 2026,\" with detailed GAAP and non-GAAP financial statements, revenue breakdowns, and operating results. The attached exhibit (EX-99.1) is the full press release with consolidated financial statements and comprehensive business updates.","company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":21042,"accession_number":"0001140361-26-029960","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Ionis Pharmaceuticals' financial results for the quarter ended June 30, 2026. The Item 2.02 filing explicitly states \"Ionis Pharmaceuticals, Inc. (the 'Company') issued a press release announcing the Company's financial results for the quarter ended June 30, 2026,\" with detailed GAAP and non-GAAP financial statements, revenue breakdowns, and operating results. The attached exhibit (EX-99.1) is the full press release with consolidated financial statements and comprehensive business updates.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T11:31:54.857173+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21042,"accession_number":"0001140361-26-029960","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Ionis Pharmaceuticals' financial results for the quarter ended June 30, 2026. The Item 2.02 filing explicitly states \"Ionis Pharmaceuticals, Inc. (the 'Company') issued a press release announcing the Company's financial results for the quarter ended June 30, 2026,\" with detailed GAAP and non-GAAP financial statements, revenue breakdowns, and operating results. The attached exhibit (EX-99.1) is the full press release with consolidated financial statements and comprehensive business updates.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T11:31:54.857173+00:00","company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","filing_date":"2026-07-29"}]}